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BULLET POINT SUMMARY 
 
What is already known:  CCL2-mediated monocyte recruitment to tissue is involved in the 
onset and development of several chronic inflammatory diseases. 
What this study adds: Pharmacological inhibition of DAG metabolism is a novel route to 
attenuate CCL2 signalling in human monocytes  
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Clinical significance: Possible novel therapies to inhibit unchecked monocyte tissue 
recruitment 
 
ABSTRACT 
 
Background and purpose 
CCL2 is an inflammatory chemokine that stimulates the recruitment of monocytes into tissue 
via activation of the GPCR CCR2.   
Experimental approach 
Freshly isolated human monocytes and THP-1 cells are used; Fura-2 loaded cells used to 
measure intracellular Ca2+ responses; transwell migration; siRNA-mediated gene knockdown. 
Key results 
We observed that CCL2 evokes intracellular Ca2+ signals and stimulates migration in THP-1 
monocytic cells and human CD14+ monocytes in a CCR2-dependent fashion.  Attenuation of 
diacylglycerol (DAG) catabolism in monocytes by inhibiting DAG kinase (R59949) or DAG 
lipase (RHC80267) activity suppresses CCL2-evoked Ca2+ signalling and transwell migration 
in monocytes.  These effects were not due to a reduction in the number of cell surface CCR2 
receptors.  The effect of DAG kinase or DAG lipase inhibition could be mimicked by the 
addition of the DAG analogue 1-oleoyl-2-acetyl-glycerol (OAG) but was not rescued by 
application of exogenous phosphatidylinositol 4,5-bisphosphate.  Suppressive effects of 
R59949, RHC80267 and OAG could be partially or fully reversed by the Gö6983 (pan PKC 
isoenzyme inhibitor) but not by Gö6976 (PKC and PKC inhibitor).  RNAi-mediated knock-
down of DAG kinase   isoenzyme modulated CCL2-evoked Ca2+ responses in THP-1 cells.   
Conclusions & Implications 
Taken together, these data suggest that DAG production resulting from CCR2 activation is 
metabolised by both DAG kinase and DAG lipase pathways in monocytes, and that 
pharmacological inhibition of DAG catabolism or application suppresses signalling on the 
CCL2-CCR2 axis via a mechanism dependent upon a PKC isoenzymes(s) that are sensitive to 
Gö6983 but not Gö6976. 
 
ABBREVIATIONS 
CCL2, monocyte chemoattractant protein 1/chemokine ligand 2; DAG, diacylglycerol; 
PBMCs, peripheral blood mononuclear cells; GADPH, glyceraldehyde 3-phosphate; AUC, 
area under the curve 
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BACKGROUND 
 
Chemokines are low molecular weight extracellular signalling peptides secreted by tissue either 
constitutively during homeostasis or de novo during an inflammatory response (Griffith et al., 
2014).  They are a diverse family of peptides (CC, CXC, CX3C and XC chemokines) with a 
key role in the tissue recruitment and interstitial migration of leukocytes and other cell types, 
as well as acting both as chemoattractants and as cues for cellular arrest (Serbina & Pamer, 
2006; Alon & Feigelson, 2012).  The biological affects of chemokines are exerted through the 
activation of G protein-coupled receptors expressed on the cell surface of target cells.  In 
addition to beneficial roles in homeostasis and immunity (Luther et al., 2002), the activity of 
chemokines is also associated with the onset and progression of chronic inflammatory diseases 
including atherosclerosis and rheumatoid arthritis (Zernecke & Weber, 2010). To this end, 
several drug discovery programmes have been initiated in an effort to pharmacologically 
intervene in chemokine receptor signalling for therapeutic benefit.  Targeting single chemokine 
receptors has proven to be difficult to translating to clinical efficiency, likely due to a level of 
redundancy between chemokine receptor subtypes.  Dual therapy has been proposed as a 
strategy to overcome this, in addition to targeting convergent second messenger pathways 
(Horuk et al., 2009). 
 
The chemokine CCL2 (monocyte chemoattractant protein-1; MCP-1) activates CCR2, a Gi-
coupled GPCR that elevates intracellular Ca2+ responses and inhibits adenylate cyclase activity 
(Campwala et al., 2014).  Classical CD14+/CD16- blood monocytes express high levels of cell 
surface CCR2 (Weber et al., 2000), in comparison to non-classical CD14+/CD16+ monocytes.  
In animal models of atherosclerosis it has been demonstrated that CCL2 signalling via CCR2 
plays an important role in the size of monocyte/macrophage vascular wall infiltrate and size of 
atherosclerotic lesion (Boring et al., 1998; Gu et al., 1998; Veillard et al., 2005; Lutgens et al., 
2005).  CCL2 is also presented on the cell surface of vascular endothelium and participates in 
monocyte recruitment by stimulating firm adhesion and transmigration to the subendothelial 
space (Wang et al., 1995; Ashida et al., 2001; Maus et al., 2002).  The importance of CCL2-
CCR2 signalling does not match by our understanding of the signal transduction mechanisms 
that regulate functional responses in human monocytes (Cronshaw et al., 2006; Webb A et al., 
2008).    
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Chemokines including CCL2 elictis intracellular Ca2+ responses in leukocytes and other cell 
types (Korniejewska et al., 2011; Campwala et al., 2014).  The responses are pertussis toxin-
sensitive and dependent upon phospholipase C (PLC) (Campwala et al., 2014).  The 
involvement of PLC suggests that diacylglycerol (DAG) would be generated during generation 
of CCL2-evoked Ca2+ responses.  DAG is a second messenger in it’s own right and can 
modulate the activity of protein kinase C (PKC) and several ion channels.  Once produced by 
cells DAG is radidly metabolised by two major pathways (1) conversion to phosphatidic acid 
by DAG kinase (Topham & Epand, 2009) and (2) hydrolysis to free fatty acid and 
monoacylglycerol by DAG lipase (Reisenberg et al., 2011).  The aim of this study was to 
investigate the role of DAG metabolising enzymes on CCL2 evoked intracellular Ca2+ 
responses and cellular function in human monocytes. 
 
MATERIALS & METHODS 
 
Isolation of CD14+ monocyte from human peripheral blood 
 
All work was undertaken with the approval of the Faculty of Medicine and Health Sciences 
Research Ethics Committee, University of East Anglia, and NHS Health Research Authority 
Ethics Committee. Healthy volunteer donor blood (National Health Service Blood and 
Transplant (Addenbrooke’s Hospital, Cambridge University Hospital, UK) was used for the 
preparation of peripheral blood mononuclear cells (PBMCs) using methodology previously 
described (Layhadi et al., 2018).  In brief, blood was layered on top of Histopaque-1077 (Sigma 
Aldrich) for centrifugation at 1000 x g for 25 mins.  Buffy coat layers were collected and 
PBMCs were counted.  CD14+ monocytes were positively selected from PBMC using anti-
CD14+ magnetic beads (Miltenyi Biotech).  Monocytes were resuspended in SBS buffer (mM): 
NaCl, 130; KCl, 5; MgCl2, 1.2; CaCl2, 1.5; D-glucose, 8; HEPES, 10; pH 7.4. 
 
Culture of THP-1 human monocyte cells 
 
THP-1 monocyte cells (CLS Cat# 300356/p804_THP-1, RRID:CVCL_0006) were cultured at 
37oC, 5% CO2 in RPMI 1640 medium containing 2mM L-glutamine and supplemented with 
10% (v/v) FBS, 50 IU/mL penicillin and 50 µg/mL streptomycin.  Cells densities were 
maintained between 1 x 105 and 1 x 106 cells/mL. 
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Intracellular Ca2+ measurements 
 
Experiments were conducted as described previously (Micklewright et al., 2018). Briefly, cells 
were treated with antagonists or vehicle controls for 30 minutes prior to challenge with 
agonists.  Measurements were made using a 96-well plate reader with rapid well injection 
(Flexstation III, Molecular Devices).  All experiments were performed in salt buffered solution 
(SBS) (pH 7.4), containing 130 mM sodium chloride, 5 mM potassium chloride, 1.2 mM 
magnesium chloride, 1.5 mM calcium chloride, 8 mM D-(+)-glucose and 10 mM HEPES. The 
cells were then loaded with 2 μM Fura-2AM (TEF Labs, Austin, TX, USA) in SBS 
supplemented with 0.01% (w/v) pluronic for 1 hour at 37 oC while being protected from light. 
The loading buffer was then removed and the cells were washed twice with SBS. Where 
applicable, the cells were incubated for a further 30 minutes with antagonists/vehicle or 
calcium-free SBS (SBS lacking 1.5 mM calcium chloride, but containing 2 mM EGTA, pH 
7.4). All antagonists were dissolved in water or DMSO.  Changes in intracellular Ca2+ 
concentration was measured as the ratio of emission at 510 nm following excitation at 340 and 
380 nm (F ratio).  Cells were treated with antagonists or vehicle controls for 30 minutes prior 
to challenge with agonists. 
 
Flow cytometry 
 
All sets were conducted at room temperature.  1x106 cells/mL were prepared in 100µL PBS 
for each marker and control experiment.  Cell were treated for 30 minutes with drugs and 
vehicle controls prior to antibody labelled.  Cells were incubated with 5µg/mL human BD Fc 
block (BD Pharmingen, New Jersey, USA) for 10 minutes. Next, (1:100) mouse monoclonal 
anti-CCR2 PE-conjugated antibody (BioLegend Cat# 357205, RRID:AB_2562058) or isotype 
control (Biolegend, USA) were added, and cells incubated in the dark for 30 minutes.  Labelled 
cells were analysesd using a CytoFLEX flow cytometer (Beckman Coulter).  Fluorescence 
intensity was read for PE using 496nm excitation and 578nm emission wavelengths, 
respectively.  Living cells were gated according to their forward and side scatter profiles, and 
then histograms were plotted to compare fluorescence intensity for anti-CCR2 and isotype 
control antibodies using CytExpert Software (version 1.2.11, Beckman Coulter). 
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siRNA-mediated gene knockdown 
 
THP-1 cells (2 x 105 final) were incubated overnight in complete RPMI (10% FBS) without 
antibiotics before cells were transfected using Dharmacon siRNA (25 nM final concentration) 
with DharmaFECT 2 transfection reagent (Dharmacon Research Inc, Cambridge, UK) using 
the manufacturer’s protocol for a 96-well format.  Scrambled siRNA and siRNA targeted 
against GADPH were used in negative and positive control experiments, respectively. 
 
RNA extraction and non-quantitative RT-PCR 
 
Total RNA was extracted from cells using Tri Reagent (Sigma Aldrich, Haverhill, UK) with 
subsequent DNase I treatment (Ambion).  Complementary DNA was synthesised from 1 µg 
total RNA using Superscript II reverse transcriptase (Invitrogen, Waltham, USA).  PCR was 
performed using a Taq polymerase readymix (Sigma Aldrich, Haverhill, UK) using the primers 
as given in Table 1. 
 
Immunocytochemistry 
 
THP-1 cells were seeded onto poly L-lysine coated coverslips followed by fixation with 
4%(w/v) paraformaldehyde for 15 mins at room temperature, and permeabilization with 
0.25%(v/v) Triton X-100 for 10 minutes.  Fixed and permeabilised cells were blocked with 1% 
(w/v) bovine serum albumin.  Cells were incubated with primary antibodies overnight at 4oC, 
followed by washing and incubation with Alexa Fluor 488-conjugated secondary antibodies.  
In negative control experiments, primary antibodies were omitted.  Rabbit polyclonal primary 
antibodies (anti-DGK, Sigma HPA049101, RRID:AB_2680630; anti-DGK, Abcam 
ab151967, RRID:AB_151967; anti-DGK, Abcam ab80693, RRID:AB_1658681; anti 
DGKAbcam ab111047, RRID:AB_10858121; anti-DAGL Abcam ab106979, 
RRID:AB_10862875; anti-DAGLwere used in conjunction with a goat anti-rabbit 
secondary antibody (Thermo Fisher Scientific Cat# A27034, RRID:AB_2536097).  Mouse 
monoclonal primary antibodies (anti-PKC, Santa Cruz Biotechnology sc-8393, 
RRID:AB_628142; anti-DGKSanta Cruz Biotechnology sc-271644, RRID:AB_10708574; 
anti-DGK, Santa Cruz Biotechnology Cat# sc-100372, RRID:AB_2245858; anti-DGK, 
Santa Cruz Biotechnology sc-137197, RRID:AB_2292802) were used in conjunction with goat 
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anti-mouse seceondary antibody ((Thermo Fisher Scientific Cat# A28175, 
RRID:AB_2536161).  Fluorescent and brightfield images were captured using a Zeiss 
AxioPlan 2ie epifluorescent microscope.  
 
Transmigration assays 
 
Transwell migration assays were performed as previously described (Micklewright et al., 
2018).  Briefly, assays were performed in 24-well plates using polyethylene terephthalate 
membrane inserts with 3µm pores.  1 x 106 cells in RPMI (no serum) with vehicle or drug 
treatment were added to the lower chamber.  Assays were performed for 2 hours at 37oC, and 
the cells that had migrated were on the underside of the transwell insert membrane using crystal 
violet staining.  Chemotactic index was calculated as the ratio of cells that migrated towards 
CCL2 over vehicle control.  These experiments were blinded. 
 
DAG assay 
DAG levels were measured using an enzyme-linked fluorescence assay (Cell Biolabs).  
Accumulation of fluorescence product has measured using 530 nm exicitation and 590 nm 
emission.  5x107 THP-1 cells in suspension were incubated at 20oC in SBS solution for 2 hours 
prior to CCL2 challenge.  Cells were exposed to inhibitors for 30 mins before challenge with 
CCL2 or vehicle.  Following cell exposure to CCL2 for 1 or 2 mins, cells were plunged on ice 
and sonicated in methanol, proceeded by extraction of organic phase in chloroform.  Total 
protein was measured by Bradford assay and used to normalise fluorescence measurements. 
 
Cell Toxicity Assay 
Potential cytotoxic effects of drug treatments were measured by quantification of lactate 
dehydrogenase (LDH) release from cells using colorimetric assay (Abcam) as for Campwala 
et al (2014).  To mimic experimental conditions, 1x106 THP-1 or freshly isolated monocytes 
were incubated with test compounds in SBS assay buffer for 30 minutes prior to conducting 
the LDH assay.  0.1% triton X-100 was used in positive control experiments. These 
experiments were blinded. 
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Data analysis & statistics 
 
The data and statistical analysis comply with the recommendations on experimental design and 
analysis in pharmacology (Curtis et al., 2015).  Data analysis was performed using Origin Pro 
9.0 software (Origin Lab, USA).  Dose-response curves were fitted assuming a Hill coefficient 
of 1, with the Hill equation used to determine the degree of cooperation.  Figure data points 
represent mean values  SEM (error bars).  N is defined as number of technical repeats or 
biological repeats (donor number) for experiments with THP-1 cells and freshy isolated CD14+ 
monocytes, respectively.  Statistical significance was determined using Student’s paired t-test 
for two sample and ANOVA for multiple sample datasets.  A confidence interval of 5% 
(P<0.05) is applied throughout. 
 
Blinding in experiments 
 
Experimental manipulations were blinded to the experimentor were technically feasible. 
 
Chemicals and reagents 
 
Unless otherwise stated, all chemicals and reagents were purchased from Sigma-Aldrich 
(Haverhill, UK). 
 
Nomenclature of targets and ligands 
 
Key protein targets in this article are hyperlinked to corresponding enteries in 
http://www.guidetopharmacology.org the common portal for data from IUPHAR/BPS Guide 
to Pharmacology (Harding et al., 2018), and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2017/2018 (Alexander et al., 2017a,b). 
 
RESULTS  
 
DAG kinase and DAG lipase inhibitors attenuate CCL2-evoked intracellular Ca2+ signals 
and migration in freshly isolated human monocytes and THP-1 monocytic cells 
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CCL2 evoked concentration-dependent intracellular Ca2+ responses in freshly isolated human 
CD14+ monocytes (Figure 1A) with an EC50 of 334nM (N=8) (Figure 1B).  These responses 
were abolished by the CCR2 selective antagonist BMSCCR222 (Figure 1C; IC50 9.21.2 nM, 
N=8).  CCL2 also evoked Ca2+ responses in THP-1 monocytes (Figure 1D) with an EC50 
4512nM (N=6) (Figure 1E), and these response were abolished by BMSCCR222 (Figure 1F; 
IC50 8.41.4nM, N=6).  These data demonstrate that CCL2 evoked intracellular Ca2+ responses 
are dependent upon CCR2 activation in both freshly isolated monocytes and the THP-1 
monocytic cells.  CCL2-evoked intracellular Ca2+ responses in freshly isolated monocytes 
(Figure 1A) and THP-1 monocytic cells (Figure 1D) was abolished following phospholipase 
C inhibition with U73122. 
 
CCR2 is a Gi-coupled GPCR that elicits intracellular Ca
2+ responses in a pertussis toxin-
sensitive and phospholipase C-dependent fashion (Campwala et al., 2014).  This signal 
transduction mechanism generates diacylglycerol (DAG), and we therefore investigated the 
impact of DAG metabolism on CCL2 evoked Ca2+ responses.  In THP-1 monocytes, R59949 
(a small molecule inhibitor of DAG kinase; de Chaffroy de Courcelles et al., 1989) attenuated 
CCL2-evoked Ca2+ signalling (Figure 2A) with a half-maximal concentration of  8.61.2µM 
(N=7) (Figure 2B).  Maximal response in THP-1 cells were inhibited by approximately 70% 
using 30µM R59949 (Figure 2C).  Similarly, CCL2-evoked Ca2+ responses were suppressed 
by RHC80267 (Figure 2D), an inhibitor of DAG lipase (Dale & Penfield, 1987).  RHC80267 
inhibited the response with a half-maximal concentration of 9.31.0 µM (N=7) (Figure 2E), 
reducing the maximal response to CCL2 by approximately 30% using 30µM RHC80267 
(Figure 2F).  In addition to CCL2-evoked Ca2+ signals, both DAG kinase or DAG lipase 
inhibition attenuated CCL2 mediate THP-1 chemotaxis (Figure 2G).  Application of CCL2 to 
THP-1 monocytic cells caused a rapid increase in cellular DAG (Figure 2H).  As for CCL2 
evoked Ca2+ signals (Figure 1D), phospholipase C inhibition with U73122 the CCL-2 evoked 
increase in cellular DAG (Figure 2H).  Both R59949 and RHC80267 significantly enhanced 
CCL2-evoked DAG elevation (Figure 2H), consistent with a role of DAG kinase and DAG 
lipase in metabolising DAG following receptor-mediated synthesis.     
 
Importantly, DAG kinase and DAG lipase inhibition attenuated CCL2-evoked signalling in 
freshly isolated human CD14+ monocytes (Figure 3).  R59949 (30µM; Figure 3A) and  
RHC80267 (30µM; Figure 3B) inhibited CCL2-evoked Ca2+ signals, inhibiting the peak Ca2+ 
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response by approximately 75% and 30% (Figure 3C); respectively.  Furthermore, both DAG 
kinase and DAG lipase inhibited CCL2 stimulated migration in freshly isolated monocytes 
(Figure 3D).  Interestingly, intracellular Ca2+ responses elicited as a consequence of formyl 
peptide receptor with N-formylmethionine-leucyl-phenylalanine (fMLP) activation on 
monocytes were insensitive to either R59949 (Figure 3E) or RHC80267 (Figure 3F), which 
suggests that DAG kinase or DAG lipase inhibition is not a generic regulator of receptor-
mediated Ca2+ signalling in monocytes (Figure 3G).  Though the focus of this study is CCL2, 
we also investigate the effect of R59949 and RHC80267 on CCL5-mediated responses in 
freshly isolated monocytes.  CCL5 has been reported to activate CCR1, CCR3 and CCR5 
receptors (de Wit et al., 2016) and is also implication with the onset and progression of 
atherosclerosis (Schober et al., 2002).  In monocytes, we observed that CCL5 mediates 
intracellular Ca2+ response through activation of CCR1, but not CCR3 or CCR5 
(Supplemental Figure 1).  The activity of CCR1 is also attenuated following following DAG 
kinase or DAG lipase inhibition.  However, the ability of CXCL1, which is implicated in 
monocyte mobilization under chronic inflammatory conditions (Drechsler et al., 2015), to 
evoked intracellular Ca2+ responses in monocytes was attenuated by inhibition of DAG kinase 
but not DAG lipase (Supplemental Figure 2).  In monocytes, we observe that CXCL1-evoked 
Ca2+ responses are mediated by CXCR2 activation (Supplemental Figure 2).   
 
Next we profiled the expression of DAG kinase and DAG lipase isoforms expressed in freshly 
isolated human CD14+ monocytes and THP-1 monocytic cells.  RT-PCR analysis of mRNA 
transcripts revealed an overlapping expression profile of DAG kinase and DAG lipase isoforms 
in CD14+ monocytes and THP-1 cells (Table 1).  For DAG kinase isoforms, , , , , , ,  
and  were expressed by both cell types, and  and  were not.  For DAG lipase isoforms, 
isoforms  and  were expressed by CD14+ monocytes and THP-1 cells (Table 1).  To 
corroborate these findings, we confirmed expression at the protein level by 
immunocytochemistry in THP-1 cells (Supplemental Figure 3). 
 
The amount of cell surface CCR2 is unaffected by DAG kinase or DAG lipase inhibition 
 
A possible mechanism underlying the reduced responsivity to CCL2 following inhibition of 
DAG metabolism is a reduction in the number of cell surface CCR2 receptors.  To test this 
hypothesis we quantified CCR2 cell surface expression in freshly isolated monocytes and THP-
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1 cells following R59949 or RHC80267 treatment by flow cytometry.  A PE-conjugated 
antibody recognising human CCR2 labelled CCR2 CD14+ monocytes (Figure 4A) and THP-
1 cells (Figure 4B) over an isotype control.  R59949 and RHC80267 were applied to cells to 
mimic the protocol used to investigating Ca2+ signalling.  Despite this, neither R59949 or 
RHC80267 had any significant effect on CCR2 cell surface expression in THP-1 cells or human 
CD14+ monocytes (Figure 4). 
 
To further understand the role of DAG kinase and DAG lipase activity in shaping CCL2-
evoked intracellular Ca2+ responses, we examined the effect of the inhibitors on the responses 
in the absence of extracellular Ca2+ to negate Ca2+ entry.  Under these conditions CCL2 evoked 
a rapidly rising but transient Ca2+ response which returned to baseline (Figure 5A).  DAG 
kinase inhibition with R5549 attenuated the peak response but lead to a sustained plateau phase 
after the transient response (Figures 5A & 5B), exemplified by an increased area under the 
curve (AUC) (Figure 5C).  Unlike DAG kinase inhibition, DAG lipase inhibition with 
RHC80267 did not effect the transient phase (Figures 5D & 5E) but did lead to a sustained 
plateau phase after the transient response (Figure 5F).  The AUC for CCL2 evoked responses 
under conditions of no external Ca2+ was significantly large following DAG lipase inhibition 
compared to DAG kinase inhibition, reflecting the difference in degree of inhibition observed 
in conditions with external Ca2+ (Figure 2).  These data suggest though DAG kinase and DAG 
lipase inhibition both suppress the global Ca2+ response to CCL2, they may do so via different 
mechanisms.    
 
Attenuative effect of DAG metabolism inhibitors is mimicked by 1-oleoyl-2-acetyl-glycerol 
but not rescued by phosphatidylinositol 4,5-bisphosphate 
 
Following receptor-mediated hydrolysis of PIP2 to DAG and IP3, DAG is used as a substrate 
for the rapid resynthesis of PIP2.  We therefore reasoned that limiting DAG metabolism could 
therefore limit PIP2 resynthesis and reduce the pool of PIP2 available for receptor-mediated 
hydrolysis, this in time could underlie the attenuated CCL2-mediated Ca2+ response observed.  
To this end, to rescue the effect of DAG kinase inhibition by supplementing with exogenous 
PIP2 (Kantonen et al., 2011).  However, in these experiments exogenous PIP2 did not limit the 
ability of R59949 to suppress CCL2-evoked Ca2+ signals (Figures 6A & 6B), suggesting PIP2 
availability did not underlie the inhibition.  We therefore attempted to address whether the 
accumulation of DAG itself following pharmacological inhibition of its metabolism could 
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mediate the attenuation of Ca2+ signalling.  We observed that 1-oleoyl-2-acetyl-sn-glycerol 
(OAG), a membrane permeable DAG analogue (Assani et al., 2017), could mimic the effect of 
DAG kinase or DAG lipase inhibition (Figure 6C) and inhibit CCL2-evoked Ca2+ signalling 
in a concentration fashion (Figure 6D).  The half-maximal concentration for OAG was 9.21.2 
µM (N=6) and the maximum CCL2 response was suppressed by approximately 70% at 30µM 
OAG (Figure 6E). 
 
Differential dependency on PKC for effects of DAG metabolism inhibitors and 1-oleoyl-2-
acetyl-glycerol 
 
As DAG is a well characterised activator of protein kinase C (PKC), we sought to test whether 
PKC activity was required for the suppressive action of OAG, DAG kinase and DAG lipase 
inhibition.  RT-PCR analysis of PKC isoform mRNA transcripts revealed expression of , , 
, , , ,  and  but not  in THP-1 cells (Table 1).  We confirmed the expression of PKC 
by immunocytochemistry (Supplemental Figure 3).  The expression pattern was the same in 
freshly isolated CD14+ monocytes except that PKC was not expressed (Table 1).  Due to the 
diverse repertoire of PKC isoforms expressed, we employed pharmacological tools that 
allowed discrimination between classical DAG and Ca2+-dependent isoforms (,  and ; 
blocked by Gö6976) and DAG dependent but Ca2+-independent isoforms (, ,  or ; blocked 
by Gö6983); Gö6983 also blocks ,  and  isoforms (Gschwendt et al., 1998; Goekjian et al., 
1999).  100nM Gö6983 (Young et al., 2014) had no effect on the control Ca2+ response to 
CCL2 (Figure 7A), however 100nM Gö6976 (Lin et al., 2011) significantly inhibited the 
response (Figure 7A). Gö6983 could rescue the response inhibited by OAG (Figure 7B), 
R59949 (Figure 7C) or RHC80267 (Figure 7D), though Gö6976 could not (Figure 7B-D).  
These data, summarised in Figure 7E, suggest that the inhibitory action of exogenous DAG 
(OAG) on DAG metabolism is mediated via a Ca2+-independent PKC isoform.  The inhibitory 
action of R59949 and RHC80267 on CCL2-evoked Ca2+ in freshly isolated monocytes could 
also be reversed by Gö6983 (N=5; Figure 7F). 
 
The Ca2+-sensitive isoform PKC regulates CCL2-evoked Ca2+ signalling in THP-1 cells 
 
A striking observation of the experiments with Gö6976 was its ability to inhibit CCL2-evoked 
Ca2+ signalling without pharmacological manipulation of DAG metabolism.  These data 
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suggest a DAG and Ca2+-dependent PKC isoform may regulate the CCL2 response, and to 
investigate this further we attempted siRNA-mediated knockdown studies of the classical Ca2+-
sensitive PKC isoform PKC.  In this experiments, siRNA delivery to THP-1 monocytes could 
inhibit CCL2-evoked Ca2+ responses versus scrambled siRNA counterparts (Figure 8A).  
Though the response peak was unaffected (Figure 8B), PKC knockdown significantly 
reduced response AUC (Figure 8C).  Quantitative RT-PCR confirmed PKC mRNA 
knockdown of approximately 50% versus scrambled siRNA counterparts (Figure 8D).  These 
data suggest the activity of PKC is required for THP-1 cells to respond to CCL2 at control 
levels. 
 
LDH release assays were performed to test for potential cytotoxic effects of inhibitor treatments 
applied throughout the study (Supplemental Figure 4). 
 
DISCUSSION  
 
This study reconfirms that CCR2 is the cognate receptor for CCL2 in human CD14+ monocytes 
and THP-1 cells.  We also provide molecular and function evidence that both DAG kinase and 
DAG lipase are functional routes for the metabolism of DAG arising from receptor-mediated 
DAG production.  These results corroborate studies in T-lymphocytes (Lee et al., 2012) and 
cancer cells (Rainero et al., 2014) that demonstrate a role for DAG kinases in modulating 
chemokine functionality.  Our data also reveal CCL5 signalling via CCR1 is reglated by both 
DAG kinase and DAG lipase activity, though lack of effect of DAG lipase inhibition on 
CXCL1-CXCR2 signalling is suggestive that this mechanism cannot be generalised for all 
chemokine action at monocytes. 
 
The data suggests that inhibitors of both of DAG kinase and DAG lipase are effective in 
reducing the efficacy of CCL2 signalling in monocytes, as the response maxima is significantly 
attenuated with little change in CCL2 EC50 values.  As the effects of DAG kinase and DAG 
lipase inhibition are mimicked by OAG and not rescued by addition of exogenous PIP2, the 
effect on CCL2 signalling of inhibiting DAG metabolism is likely to be due to the accumulation 
of DAG rather than limitation of a DAG metabolite or PIP2 synthesis.  If this is the case, the 
data suggests that there is no redundancy between kinase or lipase-dependent metabolic 
pathways for DAG in human monocytes, and processes that modulate the activity of these 
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enzymes have the potential to modulate CCL2 signalling efficacy.  Although CCR2 receptors 
are classical GPCRs and can undergo internalisation as part of mechanisms of receptor 
desensitisation (Dzenko et al., 2001; Volpe et al., 2012), the data presented here suggests the 
mechanism via which inhibition of DAG  metabolism causes loss of CCL2 signalling efficacy 
is not via a reduction in the cell surface population of CCR2 receptors.  This therefore suggests 
that the inhibitory mechanism must involve modulation of the CCR2 receptor itself, an 
auxillary subunit or a downstream effector protein.  As the effects of OAG, DAG kinase 
inhibition and DAG lipase inhibition are reversed by the broadspectrum PKC inhibitor Gö6983 
but not Gö6976, a selective inhibitor of Ca2+-dependent PKC isoforms, this is suggests that the 
inhibitor effects of DAG accumulation are mediated by a Ca2+-independent PKC isoform.  
Analysis of PKC isoform expression suggests that PKC, PKC, PKC, PKC and PKC are 
potential effectors of the inhibitory actions of DAG in monocytes.  Previous studies in 
monocytes have documented translocation of both Ca2+-dependent and Ca2+-independent PKC 
isoform from the cytoplasm to the plasma membrane upon stimulation with CCL2 (Zhang et 
al., 2003).  However opioid receptor activation, which inhibits CCL2 signalling via 
heterologous desensitisation, causes membrane recruitment of only Ca2+-independent PKC 
isoforms (Zhang et al., 2003).  Such studies support a role for Ca2+-independent PKC isoforms 
as negative regulators of CCR2 receptor activity.  The target of PKC is unlikely to be the CCR2 
receptor itself as consensus sequences for PKC-dependent phosphorylation are absent from the 
cytoplasmic sections of the receptors, although other chemokine receptor, such as CXCR4, are 
phosphorylated directly by PKC (Luo et al., 2017).   
 
The intracellular Ca2+ signal generated following CCR2 activation in monocytes most likely 
involves direct release of Ca2+ from ER stores but also Ca2+ through plasma membrane 
channels (Nardelli et al., 1999).  Experiments in the absence of extracellular Ca2+ support this 
as CCL2 can still elicit a response though transient and lacking a substantial plateau phase.  
The shape of the intracellular Ca2+ response is also differentially modulated by DAG kinase 
and DAG lipase inhibitors when the possibility of Ca2+ influx is negated.  Both R59949 and 
RHC80267 elevate the plateau phase of release, but only R59949 inhibits the peak Ca2+ 
response in the absence of extracellular Ca2+.  This suggests that there may be some 
discrimination regarding how DAG elevation, directly or indirectly, regulates the ability of 
CCR2 to release stored Ca2+ (Bartlett et al., 2015).  Monocytes express a large repertoire of 
DAG kinase isoforms and as R59949 is a pan DAG kinase inhibitor we cannot determine 
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whether redundancy exists between isoforms or whether only some subtypes participate in the 
regulation of CCR2 activity.  siRNA-mediated knockdown studies reveal DAG kinase as a 
candidate, at least in THP-1 cells.  DAG kinase has been implicated previously in immune 
cell function (Sanjuan et al., 2003).   
 
In summary, we demonstrate that inhibition of DAG kinases and DAG lipases are a novel 
pharmacological route to suppress CCL2-mediated intracellular Ca2+ signalling and migration 
in human monocytes.  We suggest the underlying mechanism involves DAG accumulation and 
activation of Ca2+-independent PKC isoforms. 
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Figure 1 CCR2 is the cognate receptor for CCL2 in freshly isolated human monocytes 
and THP-1 monocytic cells.  (A)  Averaged (N=8) intracellular Ca2+ response to CCL2 (50 
ng/mL) in freshly isolated CD14+ human monocytes. Response in the presence (open circles) 
and absence (closed circles) of 5M U73122 (N=6; P<0.05). (B) Concentration-response 
curve for CCL2-evoked responses in freshly isolated monocytes (N=8; EC50 = 334nM). (C) 
Concentration-inhibition curve for selective CCR2 receptor antagonist BMSCCR222 (IC50 = 
91nM; N=8) against Ca2+ responses evoked by CCL2 (50 ng/mL) in freshly isolated 
monocytes. (D) Averaged (N=6) intracellular Ca2+ response to CCL2 (50 ng/mL) in THP-1 
cells. Response in the presence (open circles) and absence (closed circles) of 5M U73122 
(N=6; P<0.05). (E) Concentration-response curve for CCL2-evoked responses in THP-1 cells 
(N=6; EC50 = 4512nM). (F) Concentration-inhibition curve for BMSCCR222 (IC50 = 
81nM; N=6) against Ca2+ responses evoked by CCL2 (50 ng/mL) in THP-1 cells.  
Responses are in the presence of vehicle alone (closed circles) or in the presence of U73122 
(open circles).  F ratio is the Ca2+ response as measured by the Fura-2 emission intensity ratio 
when excited at 340 and 380 nm.  Data in concentration-response/inhibition curves is 
expressed as a percentage of the control response in the presence of vehicle alone. 
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Figure 2 Inhibitors of DAG kinase and DAG lipase attenuate CCL2-evoked Ca2+ 
signalling and migration in THP-1 cells. (A) Effect of DAG kinase inhibitor R59949 
(30µM) on Ca2+ responses evoked by CCL2 (50 ng/mL) (N=7).  Averaged responses are 
shown in the presence of vehicle (closed circles) and inhibitor (open circles).  (B) R59949 
concentration-inhibition curve (IC50 = 91µM; N=7) against Ca2+ responses evoked by CCL2 
(50 ng/mL). (C)  Effect of 30µM R59949 on CCL2 concentration-response curve (N=7). (D) 
Effect of DAG lipase inhibitor RHC80267 (30µM) on Ca2+ responses evoked by CCL2 (50 
ng/mL) (N=7). Averaged responses are shown in the presence of vehicle (closed circles) and 
inhibitor (open circles).  (E) RHC80267 concentration-inhibition curve (IC50 = 91µM; N=7) 
against Ca2+ responses evoked by CCL2 (50 ng/mL). (F)  Effect of 30µM RHC80267 on 
CCL2 concentration-response curve (N=7).  (G) Effect of R59949 (30µM) and RHC80267 
(30µM) on THP-1 transmigration to CCL2 (3 ng/mL).  * denotes P<0.05 versus vehicle and # 
denotes P<0.05 versus CCL2 alone (N=8).  F ratio is the Ca2+ response as measured by the 
Fura-2 emission intensity ratio when excited at 340 and 380 nm.  Data in concentration-
response/inhibition curves is expressed as a percentage of the control response in the 
presence of vehicle alone. (H) Biochemical measurement of DAG changes in THP-1 cells.  
Cells preincubated for 30 minutes with either U73122 (5µM), R59949 (30µM) or RHC80267 
(30µM) prior to CCL2 challenge (50ng/mL) for 1 or 2 mins (N=6). Vehicle control; cells are 
are preincubated with vehicle and not challenged with CCL2.  * denotes P<0.05 versus CCL2 
alone. 
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Figure 3 Responses to CCL2 but not fMLP are attenuated by DAG kinase and DAG 
lipase inhibitors in freshly isolated human monocytes. Effect of (A) DAG kinase inhibitor 
R59949 (30µM) and (B) DAG lipase inhibitor RHC80267 (30µM) on Ca2+ responses evoked 
by CCL2 (50 ng/mL) in monocytes (N=8).  Averaged responses are shown in the presence of 
vehicle (closed circles) and inhibitor (open circles).  (C) Bar chart showing effect of R59949 
(30µM) and RHC80267 (30µM) on the peak Ca2+ response evoked by CCL2 (50 ng/mL) 
(N=8).  (D)  Effect of R59949 (30µM) and RHC80267 (30µM) on freshly isolated monocyte 
transmigration to CCL2 (3 ng/mL).  * denotes P<0.05 versus vehicle and # denotes P<0.05 
versus CCL2 alone (N=8).  Lack of effect of (E) R59949 (30µM) or (F) RHC80267 (30µM) 
on Ca2+ responses evoked by fMLP (10 µM) in monocytes (N=6).  Averaged responses are 
shown in the presence of vehicle (closed circles) and inhibitor (open circles). (G) Bar chart 
showing lack of effect of R59949 (30µM) and RHC80267 (30µM) on peak Ca2+ response 
evoked by fMLP (10 µM) (N=6).  F ratio is the Ca2+ response as measured by the Fura-2 
emission intensity ratio when excited at 340 and 380 nm.  Data in inhibition experiments is 
expressed as a percentage of the control response in the presence of vehicle alone. 
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Figure 4 DAG kinase or DAG lipase inhibition does not reduced the cell surface 
population of CCR2 receptors in freshly isolated monocytes and THP-1 cells.  3 
representative (N=6) flow cytometry profiles of freshly isolated CD14+ monocytes (A) and  
THP-1 cells (B) labelled with anti-CCR2 antibodies or isotype control.  Cell are treated with 
vehicle control, R59949 (30µM) or RHC80267 (30µM).  Anti-CCR2 cell surface 
immunoreactivity is indistinguishable between vehicle control and test groups. 
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Figure 5 Effects of DAG kinase and DAG lipase inhibitors on CCL2-evoked Ca2+ 
responses in THP-1 cells in the absence of extracellular Ca2+.  (A) Averaged (N=8) 
intracellular Ca2+ responses evoked by CCL2 (50ng/mL) in the absence of extracellular Ca2+ 
and presence (open circles) and absence (closed circles) of R59949 (30µM).  (B) and (C) 
show the effect of R59949 on intracellular Ca2+ peak and area under the curve (AUC) in the 
absence of extracelluar Ca2+ (N=8).  (D) Averaged (N=8) intracellular Ca2+ responses evoked 
by CCL2 (50ng/mL) in the absence of extracellular Ca2+ and presence (open circles) and 
absence (closed circles) of RHC80267 (30µM).  (E) and (F) show the effect of R59949 on 
intracellular Ca2+ peak and AUC in the absence of extracelluar Ca2+ (N=8).  * denotes P<0.05 
versus vehicle control for all. 
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Figure 6  Application of exogenous PIP2 does not rescue CCL2-evoked Ca2+ response 
following DAG kinase inhibition but inhibition is mimicked by OAG in THP-1 cells.  (A) 
CCL2-evoked (50ng/mL) intracellular Ca2+ responses in the presence of vehicle control 
(closed circles),  R59949 (open circles; 30µM) or R59949 plus exogenous PIP2 (squares; 
300µM) (N=8).  (B) Bar chart showing average peak intracellular Ca2+ responses.  * denotes 
P<0.05 versus vehicle control.  (C) CCL2-evoked (50ng/mL) intracellular Ca2+ responses in 
the presence of vehicle control (closed circles) or cell permeable DAG analogue, OAG (open 
circles) (N=8).  (D) Concentration-inhibition curve for OAG effect on intracellular Ca2+ 
responses evoked by CCL2 (50ng/mL) (N=8). (E) Effect of OAG (30µM) on CCL2 
concentration-response curve in THP-1 cells (IC50 91µM; N=6).  Responses are in the 
presence of vehicle control (closed circles) or OAG (open circles).   F ratio is the Ca2+ 
response as measured by the Fura-2 emission intensity ratio when excited at 340 and 380 nm.  
Data in inhibition experiments is expressed as a percentage of the control response in the 
presence of vehicle alone. 
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Figure 7 Effect of inhibiting Ca2+-dependent and Ca2+-independent PKC isoforms on 
CCL2-evoked responses following inhibition of DAG kinase and DAG lipase in THP-1 
cells and freshly isolated monocytes. (A) CCL2-evoked intracellular Ca2+ responses in 
THP-1 cells the presence of vehicle control, Gö6976 (100nM) or Gö6983 (100nM) (N=8). 
(B)  CCL2-evoked intracellular Ca2+ responses in THP-1 cells the presence of vehicle control 
and OAG (30µM) in the presence and absence of Gö6976 or Gö6983 (N=8). (C) CCL2-
evoked intracellular Ca2+ responses in THP-1 cells the presence of vehicle control, and 
R59949 (30µM) in the presence and absence of Gö6976 or Gö6983 (N=8). (D) CCL2-evoked 
intracellular Ca2+ responses in THP-1 cells the presence of vehicle control, and RHC80267 
(30µM) in the presence and absence of Gö6976 or Gö6983 (N=8). (E) Barchart showing 
averaged data from experiments (A-D). (F) Barchart showing CCL2-evoked Ca2+ responses 
in freshly isolated monocytes and the effect of R59949 (30µM) and RHC80267 (30µM), in 
the presence and absence of Gö6983 (100nM) (N=8).  All intracellular Ca2+ responses are 
evoked by 50 ng/mL CCL2.  * denotes P<0.05 versus CCL2 and # denotes P<0.05 for 
combined inhibitors over either OAG, R59949 or RHC80267 alone.  F ratio is the Ca2+ 
response as measured by the Fura-2 emission intensity ratio when excited at 340 and 380 nm.  
Data in inhibition experiments is expressed as a percentage of the control response in the 
presence of vehicle alone. 
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Figure 8  Effect of DAG kinase  knockdown of CCL2-evoked Ca2+ responses in THP-1 
cells. (A) Averaged intracellular Ca2+ response evoked by CCL2 in THP-1 cells transfected 
with scrambled siRNA (closed circles) or DAG kinase alpha targeted siRNA (open circles) 
(N=8). Barcharts showing peak (B) and area under the curve (C) intracellular Ca2+ responses 
evoked by CCL2 in scrambled, GAPDH knockdown or DAG kinase alpha knockdown THP-
1 cells (N=8). (D) qRT-PCR analysis of GAPDH or DAG kinase alpha mRNA transcripts in 
scrambled and knockdown THP-1 cells (N=8).  F ratio is the Ca2+ response as measured by 
the Fura-2 emission intensity ratio when excited at 340 and 380 nm.  Responses evoked by 50 
ng/mL CCL2 for all experiments.  * denotes P<0.05 versus scrambled control cells in all 
experiments. Data in each experiment is expressed as a percentage of the Ca2+ response to 
ionomycin to control of cell number in knockdown studies. 
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Table 1  Expression of DAG kinase, DAG lipase and PKC mRNA transcripts in CD14+ monocytes 
and THP-1 cells.  Data is representative of 5 donors/independent experiments.  Sense and anti-
sense primer sequences used for non-quantitative RT-PCR are given beneath each gene assayed.  
Positive control PCR products were generated for all primers sets using human brain cDNA 
template. 
 
Gene   Name                  CD14+ monocytes  THP-1 cells 
 
DGKA   diacylglycerol kinase alpha     expressed  expressed 
 
Sense:  CAACAGGAGGCAAAACTGGC 
Anti-sense: TGCCACCTAGAGATCCACGA 
  
DGKB   diacylglycerol kinase beta  not expressed             not expressed 
 
Sense:  TCTGTGTGCAATGGAGGCAT 
Anti-sense: CCACCCACAACAATCTGTCCA 
 
DGKD   diacylglycerol kinase delta  expressed  expressed
  
 
Sense:  TTATTGGTTGCACGCACAGC 
Anti-sense: CAGACCATCATCAAAGAGGGGA 
  
DGKE   diacylglycerol kinase epsilon  expressed  expressed 
 
Sense:  AGAGGGTAAGTCTCGTCCCC 
Anti-sense: CTCTGGGAACAGGCAACGAT 
 
DGKG   diacylglycerol kinase gamma  expressed  expressed 
 
Sense:  GACTTCTCACCTGGCCTGTC 
Anti-sense: GTCCCTCGGTCTTCAAGCTC 
 
DGKH   diacylglycerol kinase eta  expressed  expressed 
 
Sense:  TATCCCCAGATCCAGGCTGT 
Anti-sense: CAGATGCAGCTATGCTCCCA 
 
DGKI   diacylglycerol kinase iota  not expressed               not expressed 
 
Sense:  TCCAGTGTGACATGGGCATC 
Anti-sense: GGTACCTGAATCCACGGCAA 
 
DGKK   diacylglycerol kinase kappa  expressed            not expressed 
 
Sense:  CACTGGGCAATGCGATGATG 
Anti-sense: TAACCAGACAAGCCCACGAC 
 
DGKQ   diacylglycerol kinase theta  expressed  expressed 
 
Sense:  AGGCTCCGAGAGTGACTGAT 
Anti-sense: GTGAACCCCAAGAGTGGAGG 
 
DGKZ   diacylglycerol kinase zeta  expressed  expressed 
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Sense:  GGCTCAGGTCGAAGACTTGT 
Anti-sense: CAGGATGCTGCAGAAGTCAGT 
  
DAGLA  diacylglycerol lipase alpha  expressed  expressed
  
 
Sense:  TGTCGGATGGCACAATGTCA 
Anti-sense: GAGCCCAGGATGGAGGTGG 
 
DAGLB  diacylglycerol lipase beta  expressed  expressed
  
 
Sense:  GTTCGTACCACAAACCGTGC 
 
Anti-sense: CTCCCAGGAAGCTGATCTGGA 
 
PRKCA  protein kinase C alpha   expressed  expressed
  
 
Sense:  CCTTTGCCACACACTTTGGG  
Anti-sense: TGACCGAGTGAAACTCACGG 
 
PRKCB  protein kinase C beta   expressed  expressed 
 
Sense:  TCTCTTGTCTCTAGCTTTTGGCT 
Anti-sense: CCCGGAAGAAAAGACGACCA 
 
PRKCG  protein kinase C gamma  not expressed               not expressed 
 
Sense:  TCTAGAATGGGACAGGGGGT 
Anti-sense: CAGGACAGCCTCCCTTCGAT 
 
PRKCD  protein kinase C delta   expressed  expressed 
 
Sense:  TGTTGAGGCCCCAGACAAAG 
Anti-sense: TGGTGGTTGGTGCGTTGTAG 
 
PRKCE  protein kinase C epsilon  expressed  expressed 
 
Sense:  GGTGCAGACTTGACACTGGT 
Anti-sense: GAACCCGGCGAGGAAATACA 
 
PRKCH  protein kinase C eta   not expressed  expressed 
 
Sense:  GATCCACCCAACCCTCGAA 
Anti-sense: GCGGGGGTTCTGTGAACTTG 
 
PRKCQ  protein kinase C theta   expressed  expressed 
 
Sense:  TTAAGCAGCGAGCCTGTTGA 
Anti-sense: GAAACCTCAAGGCCGAATGC 
 
PRKCI  protein  kinase C iota    expressed  expressed 
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Sense:  CCCTGGTGTTCATTGCCTCT 
Anti-sense: GGCCTTTGCAATGAGGTTCG 
 
PRKCZ protein kinase C zeta    expressed  expressed 
 
Sense:  TGGCTTAAGGTCCTCCGAGT 
Anti-sense: GAGTTCCGCGGAGTTGACC 
 
 
